{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:02:33Z","timestamp":1784005353314,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012399","name":"BARDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jtha.2024.08.019","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T16:49:06Z","timestamp":1726246146000},"page":"3532-3541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26\u2013vectored vaccines"],"prefix":"10.1016","volume":"22","author":[{"given":"Hendy","family":"Kristyanto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Slaets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esm\u00e9e","family":"Braams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Scheys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Heesbeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"C\u00e1rdenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgi","family":"Shukarev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Scheper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Sadoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"L\u00fchn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Struyf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.08.019_bib1","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1016\/j.vaccine.2022.05.047","article-title":"Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials","volume":"40","author":"Sadoff","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jtha.2024.08.019_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial","volume":"22","author":"Ishola","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jtha.2024.08.019_bib3","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.08.019_bib4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M21-4502","article-title":"Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, December 2020 to August 2021","volume":"175","author":"See","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.08.019_bib5","author":"Shimabukuro"},{"key":"10.1016\/j.jtha.2024.08.019_bib6","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.vaccine.2024.01.045","article-title":"Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data","volume":"42","author":"Sch\u00f6nborn","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.jtha.2024.08.019_bib7","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1016\/j.vaccine.2023.07.013","article-title":"Thrombosis with thrombocytopenia syndrome: a database review of clinical trial and post-marketing experience with Ad26.COV2.S","volume":"41","author":"Struyf","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jtha.2024.08.019_bib8","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.08.019_bib9","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.08.019_bib10","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMc2210813","article-title":"Vaccine-induced immune thrombocytopenia and thrombosis after the Sputnik V vaccine","volume":"387","author":"Herrera-Comoglio","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.08.019_bib11","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1016\/j.vaccine.2022.06.014","article-title":"Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: description of a series of 39 cases in Brazil","volume":"40","author":"de Oliveira","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jtha.2024.08.019_bib12","article-title":"Case report: vaccine-induced immune thrombotic thrombocytopenia complicated by acute cerebral venous thrombosis and hemorrhage after AstraZeneca vaccines followed by Moderna COVID-19 vaccine booster and surgery","volume":"13","author":"Chen","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.jtha.2024.08.019_bib13","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jth.15604","article-title":"Thrombosis and thrombocytopenia after HPV vaccination","volume":"20","author":"Johansen","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.08.019_bib14","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1038\/s41467-022-32946-1","article-title":"NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia","volume":"13","author":"Leung","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtha.2024.08.019_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/blood.2021014588","article-title":"Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT","volume":"140","author":"Kanack","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.08.019_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-021-03744-4","article-title":"Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia","volume":"596","author":"Huynh","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2024.08.019_bib17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1055\/s-0042-1758818","article-title":"Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: a narrative review","volume":"49","author":"Warkentin","year":"2023","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.08.019_bib18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/vox.13633","article-title":"Laboratory approach for vaccine-induced thrombotic thrombocytopenia diagnosis in the Netherlands","volume":"119","author":"Meier","year":"2024","journal-title":"Vox Sang"},{"issue":"Suppl 2","key":"10.1016\/j.jtha.2024.08.019_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ijlh.14075","article-title":"Platelet factor 4 triggers thrombo-inflammation by bridging innate and adaptive immunity","volume":"45","author":"Greinacher","year":"2023","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2024.08.019_bib20","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/jth.13955","article-title":"Platelets kill bacteria by bridging innate and adaptive immunity via platelet factor 4 and Fc\u03b3RIIA","volume":"16","author":"Palankar","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.08.019_bib21","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1309\/AJCPG0MNR5NGKNFX","article-title":"Platelet factor 4\/heparin antibodies in blood bank donors","volume":"134","author":"Hursting","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtha.2024.08.019_bib22","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.08.019_bib23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/bloodadvances.2022007336","article-title":"Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S","volume":"7","author":"Huynh","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.08.019_bib24","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2021014214","article-title":"Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient","volume":"139","author":"Sch\u00f6nborn","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.08.019_bib25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ajh.26488","article-title":"Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies","volume":"97","author":"Kanack","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.08.019_bib26","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2213361119","article-title":"Anti-PF4 antibodies associated with disease severity in COVID-19","volume":"119","author":"Liu","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.08.019_bib27","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1111\/jth.15352","article-title":"An observational study to identify the prevalence of thrombocytopenia and anti-PF4\/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination","volume":"19","author":"S\u00f8rvoll","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.08.019_bib28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/ijlh.13774","article-title":"Low clinical utility of testing for anti-platelet factor 4 in asymptomatic individuals after ChAdOx1 nCoV-19 vaccine","volume":"44","author":"Barefah","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2024.08.019_bib29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/jth.14369","article-title":"Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia","volume":"17","author":"Huynh","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.08.019_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood.2021012217","article-title":"Frequency of positive anti-PF4\/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2","volume":"138","author":"Thiele","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.08.019_bib31","article-title":"Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany","volume":"12","author":"Thiele","year":"2022","journal-title":"Lancet Reg Health Eur"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624005361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624005361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T06:22:47Z","timestamp":1732947767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624005361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1538783624005361"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.08.019","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26\u2013vectored vaccines","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}